The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NXTC | -47.79% | -93.26% | -41.69% | -96% |
| S&P | +14.08% | +93.57% | +14.12% | +138% |
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
The company cited patient safety concerns and the current strains on hospitals as the reasons for the postponements.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.53M | 23.9% |
| Market Cap | $15.68M | -59.1% |
| Market Cap / Employee | $0.36M | 0.0% |
| Employees | 43 | -47.6% |
| Net Income | -$8.62M | 25.3% |
| EBITDA | -$8.41M | 28.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.32M | -73.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.41M | -18.1% |
| Short Term Debt | $0.33M | 17.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -89.28% | -38.5% |
| Return On Invested Capital | -43.19% | -13.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.27M | 46.1% |
| Operating Free Cash Flow | -$6.27M | 45.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.33 | 0.24 | 0.41 | 0.43 | -14.64% |
| Price to Tangible Book Value | 3.42 | 2.47 | 2.77 | 0.43 | -91.96% |
| Enterprise Value to EBITDA | 3.49 | 3.33 | 0.63 | 1.03 | -61.11% |
| Return on Equity | -61.9% | -63.9% | -104.1% | -116.9% | 101.83% |
| Total Debt | $5.95M | $5.84M | $5.31M | $4.75M | -16.34% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
